{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:25:07Z","timestamp":1789385107624,"version":"build-2803163510"},"reference-count":75,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","mayoclinicproceedings.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.mayocp.2016.02.012","type":"journal-article","created":{"date-parts":[[2016,5,26]],"date-time":"2016-05-26T14:37:46Z","timestamp":1464273466000},"page":"713-725","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"title":["Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs"],"prefix":"10.1016","volume":"91","author":[{"given":"Chul","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.mayocp.2016.02.012_bib1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S1040-8428(02)00008-2","article-title":"Oncology drug development: United States Food and Drug Administration perspective","volume":"42","author":"Hirschfeld","year":"2002","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"10.1016\/j.mayocp.2016.02.012_bib2","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1200\/JCO.2003.08.072","article-title":"End points and United States Food and Drug Administration approval of oncology drugs","volume":"21","author":"Johnson","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 2","key":"10.1016\/j.mayocp.2016.02.012_bib3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1634\/theoncologist.13-S2-19","article-title":"Endpoints for assessing drug activity in clinical trials","volume":"13","author":"Pazdur","year":"2008","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.mayocp.2016.02.012_bib4","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/jnci\/djp515","article-title":"Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007","volume":"102","author":"Sridhara","year":"2010","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"26","key":"10.1016\/j.mayocp.2016.02.012_bib5","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.mayocp.2016.02.012_bib6","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1056\/NEJMp1107201","article-title":"Reputation and precedent in the bevacizumab decision","volume":"365","author":"Carpenter","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.mayocp.2016.02.012_bib7","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jamainternmed.2015.2829","article-title":"The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses","volume":"175","author":"Prasad","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.mayocp.2016.02.012_bib8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/biostatistics\/1.1.49","article-title":"The validation of surrogate endpoints in meta-analyses of randomized experiments","volume":"1","author":"Buyse","year":"2000","journal-title":"Biostatistics"},{"issue":"2","key":"10.1016\/j.mayocp.2016.02.012_bib9","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/sim.4780110204","article-title":"Statistical validation of intermediate endpoints for chronic diseases","volume":"11","author":"Freedman","year":"1992","journal-title":"Stat Med"},{"key":"10.1016\/j.mayocp.2016.02.012_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1471-2288-12-27","volume":"12","author":"Lassere","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"10.1016\/j.mayocp.2016.02.012_bib11","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/jnci\/84.6.407","article-title":"Statistical model to determine the relationship of response and survival in patients with advanced ovarian cancer treated with chemotherapy","volume":"84","author":"Torri","year":"1992","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.mayocp.2016.02.012_bib12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/sim.2319","article-title":"Statistical evaluation of biomarkers as surrogate endpoints: a literature review","volume":"25","author":"Weir","year":"2006","journal-title":"Stat Med"},{"issue":"8","key":"10.1016\/j.mayocp.2016.02.012_bib13","doi-asserted-by":"crossref","DOI":"10.3310\/hta13080","article-title":"The use of surrogate outcomes in model-based cost-effectiveness analyses: a survey of UK Health Technology Assessment reports","volume":"13","author":"Taylor","year":"2009","journal-title":"Health Technol Assess"},{"issue":"2","key":"10.1016\/j.mayocp.2016.02.012_bib14","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s10147-009-0885-4","article-title":"Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials","volume":"14","author":"Shi","year":"2009","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.mayocp.2016.02.012_bib15","unstructured":"Institute for Quality and Efficiency in Health Care. Validity of surrogate endpoints in oncology: executive summary. https:\/\/www.iqwig.de\/download\/A10-05_Executive_Summary_v1-1_Surrogate_endpoints_in_oncology.pdf. Published 2011. Accessed July 23,\u00a02015."},{"issue":"12","key":"10.1016\/j.mayocp.2016.02.012_bib16","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1001\/jamainternmed.2015.5868","article-title":"Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of us food and drug administration approvals","volume":"175","author":"Kim","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"11","key":"10.1016\/j.mayocp.2016.02.012_bib17","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood-2010-09-307645","article-title":"Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients","volume":"117","author":"Gay","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.mayocp.2016.02.012_bib18","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/jco.2008.26.15_suppl.2024","article-title":"Correlation of response with survival endpoints in patients with newly diagnosed and recurrent glioblastoma (GBM) treated on prospective North Central Cancer Treatment Group (NCCTG) clinical trials","volume":"26","author":"Jaeckle","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.mayocp.2016.02.012_bib19","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1182\/blood-2013-03-490128","article-title":"Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities","volume":"121","author":"Jain","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.mayocp.2016.02.012_bib20","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jval.2013.07.004","article-title":"Complete cytogenetic response and major molecular response as surrogate outcomes for overall survival in first-line treatment of chronic myelogenous leukemia: a case study for technology appraisal on the basis of surrogate outcomes evidence","volume":"16","author":"Oriana","year":"2013","journal-title":"Value Health"},{"issue":"2, suppl 2","key":"10.1016\/j.mayocp.2016.02.012_bib21","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/shem.2003.50042","article-title":"The cytogenetic response as a surrogate marker of survival","volume":"40","author":"Rosti","year":"2003","journal-title":"Semin Hematol"},{"issue":"10","key":"10.1016\/j.mayocp.2016.02.012_bib22","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3324\/haematol.11534","article-title":"Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma","volume":"92","author":"van de Velde","year":"2007","journal-title":"Haematologica"},{"issue":"14","key":"10.1016\/j.mayocp.2016.02.012_bib23","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/j.ejca.2011.06.014","article-title":"Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients","volume":"47","author":"Kong","year":"2011","journal-title":"Eur J Cancer"},{"issue":"34","key":"10.1016\/j.mayocp.2016.02.012_bib24","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1200\/JCO.2014.55.2836","article-title":"Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies","volume":"32","author":"Berruti","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"9938","key":"10.1016\/j.mayocp.2016.02.012_bib25","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.mayocp.2016.02.012_bib26","unstructured":"Ciccarese M, Bria E, Cuppone F, et\u00a0al. Disease-free survival (DFS) as surrogate end point for overall survival (OS) in adjuvant aromatase inhibitors (AIs) trials for breast cancer (BC): meta-analysis of 10 randomized clinical trials (RCTs) exploring the magnitude of the benefit. Paper presented at: American Society of Clinical Oncology (ASCO) 43rd Annual Meeting; June 1-5, 2007; Chicago, IL."},{"issue":"6","key":"10.1016\/j.mayocp.2016.02.012_bib27","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10147-011-0231-5","article-title":"Surrogacy of tumor response and progression-free survival for overall survival in metastatic breast cancer resistant to both anthracyclines and taxanes","volume":"16","author":"Matsubara","year":"2011","journal-title":"Int J Clin Oncol"},{"issue":"11","key":"10.1016\/j.mayocp.2016.02.012_bib28","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/sj.bjc.6602858","article-title":"Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer","volume":"93","author":"Hackshaw","year":"2005","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.mayocp.2016.02.012_bib29","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1200\/JCO.2007.10.8407","article-title":"Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer","volume":"26","author":"Burzykowski","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.mayocp.2016.02.012_bib30","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1017\/S0266462308080495","article-title":"Progression-free survival as a surrogate endpoint in advanced breast cancer","volume":"24","author":"Miksad","year":"2008","journal-title":"Int J Technol Assess Health Care"},{"issue":"3","key":"10.1016\/j.mayocp.2016.02.012_bib31","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/annonc\/mdm486","article-title":"Correlation of changes between 2-year disease-free survival and 5-year overall survival in adjuvant breast cancer trials from 1966 to 2006","volume":"19","author":"Ng","year":"2008","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.mayocp.2016.02.012_bib32","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1038\/sj.bjc.6604759","article-title":"Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer","volume":"99","author":"Sherrill","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.mayocp.2016.02.012_bib33","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.2147\/OTT.S63302","article-title":"Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer","volume":"7","author":"Beauchemin","year":"2014","journal-title":"Onco Targets Ther"},{"issue":"1","key":"10.1016\/j.mayocp.2016.02.012_bib34","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0169-5002(91)90018-2","article-title":"Response rate as criterium to evaluate chemotherapy in non-small cell lung cancer","volume":"7","author":"Splinter","year":"1991","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"14","key":"10.1016\/j.mayocp.2016.02.012_bib35","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1016\/S0959-8049(97)00325-0","article-title":"Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working Party","volume":"33","author":"Paesmans","year":"1997","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.mayocp.2016.02.012_bib36","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1023\/A:1008473003445","article-title":"Response rate as an endpoint for evaluating new cytotoxic agents in phase II trials of non-small-cell lung cancer","volume":"9","author":"Sekine","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.mayocp.2016.02.012_bib37","unstructured":"Bruzzi P, Sormani M, Tiseo M, Boni L, Rosell R, Ardizzoni A. Tumor response to chemotherapy as a surrogate endpoint of survival in advanced non-small cell lung cancer (NSCLC): results of an individual patients data meta-analysis. Paper presented at: American Society of Clinical Oncology (ASCO) 43rd Annual Meeting; June 1-5, 2007; Chicago, IL."},{"issue":"8","key":"10.1016\/j.mayocp.2016.02.012_bib38","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1097\/JTO.0b013e3181a94a2f","article-title":"Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib","volume":"4","author":"Tsujino","year":"2009","journal-title":"J\u00a0Thorac Oncol"},{"issue":"1","key":"10.1016\/j.mayocp.2016.02.012_bib39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/JTO.0b013e3181c0a313","article-title":"Endpoints in phase II trials for advanced non-small cell lung cancer","volume":"5","author":"Mandrekar","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"issue":"11","key":"10.1016\/j.mayocp.2016.02.012_bib40","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1007\/s00432-012-1278-z","article-title":"Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib","volume":"138","author":"Li","year":"2012","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"9","key":"10.1016\/j.mayocp.2016.02.012_bib41","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1200\/JCO.2014.59.0489","article-title":"Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses","volume":"33","author":"Blumenthal","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.mayocp.2016.02.012_bib42","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S1470-2045(06)70800-2","article-title":"Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis","volume":"7","author":"Johnson","year":"2006","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2016.02.012_bib43","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.critrevonc.2013.05.004","article-title":"Activity endpoints reported in soft tissue sarcoma phase II trials: quality of reported endpoints and correlation with overall survival","volume":"88","author":"Penel","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"10.1016\/j.mayocp.2016.02.012_bib44","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ygyno.2010.01.040","article-title":"Assessment of tumor response as a surrogate endpoint of survival in recurrent\/platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group study","volume":"117","author":"Rose","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.mayocp.2016.02.012_bib45","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2147\/GICTT.S61671","article-title":"Association between time to disease progression end points and overall survival in patients with neuroendocrine tumors","volume":"4","author":"Singh","year":"2014","journal-title":"Gastrointest Cancer Targets Ther"},{"issue":"3","key":"10.1016\/j.mayocp.2016.02.012_bib46","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(14)70007-5","article-title":"Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials","volume":"15","author":"Flaherty","year":"2014","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.mayocp.2016.02.012_bib47","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1093\/annonc\/mdr487","article-title":"Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer","volume":"23","author":"Hayashi","year":"2012","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.mayocp.2016.02.012_bib48","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1023\/A:1008303921033","article-title":"Progressive disease rate as a surrogate endpoint of phase II trials for non-small-cell lung cancer","volume":"10","author":"Sekine","year":"1999","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2016.02.012_bib49","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/ajco.12199","article-title":"Relationship between progression-free survival and overall survival in patients with advanced non-small cell lung cancer treated with anticancer agents after first-line treatment failure","volume":"11","author":"Suzuki","year":"2015","journal-title":"Asia Pac J Clin Oncol"},{"issue":"3","key":"10.1016\/j.mayocp.2016.02.012_bib50","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.cllc.2012.09.006","article-title":"Postprogression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy","volume":"14","author":"Hayashi","year":"2013","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"10.1016\/j.mayocp.2016.02.012_bib51","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.lungcan.2012.10.007","article-title":"Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer","volume":"79","author":"Hotta","year":"2013","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.mayocp.2016.02.012_bib52","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(13)70158-X","article-title":"Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data","volume":"14","author":"Mauguen","year":"2013","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.mayocp.2016.02.012_bib53","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/JTO.0b013e3181989bd2","article-title":"Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer","volume":"4","author":"Hotta","year":"2009","journal-title":"J\u00a0Thorac Oncol"},{"issue":"1","key":"10.1016\/j.mayocp.2016.02.012_bib54","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/cncr.28221","article-title":"Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma","volume":"120","author":"Halabi","year":"2014","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.mayocp.2016.02.012_bib55","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1002\/cncr.25750","article-title":"Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy","volume":"117","author":"Heng","year":"2011","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.mayocp.2016.02.012_bib56","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.critrevonc.2014.08.001","article-title":"Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma: correlation with overall survival, benchmarking and power analysis","volume":"93","author":"Bria","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"10.1016\/j.mayocp.2016.02.012_bib57","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/annonc\/mdu267","article-title":"Evaluating surrogacy metrics and investigating approval decisions of progression-free survival (PFS) in metastatic renal cell cancer: a systematic review","volume":"26","author":"Johnson","year":"2015","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.mayocp.2016.02.012_bib58","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.clgc.2013.07.012","article-title":"Surrogate end points and postprogression survival in renal cell carcinoma: an analysis of first-line trials with targeted therapies","volume":"11","author":"Petrelli","year":"2013","journal-title":"Clin Genitourin Cancer"},{"issue":"7","key":"10.1016\/j.mayocp.2016.02.012_bib59","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/bjc.2012.367","article-title":"Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma","volume":"107","author":"Delea","year":"2012","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.mayocp.2016.02.012_bib60","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.ejca.2015.02.011","article-title":"Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: a systematic review and pooled-analysis","volume":"51","author":"Petrelli","year":"2015","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.mayocp.2016.02.012_bib61","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/annonc\/mdr492","article-title":"Randomized controlled trials in the era of molecular oncology: methodology, biomarkers, and end points","volume":"23","author":"Kay","year":"2012","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.mayocp.2016.02.012_bib62","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1200\/JCO.2013.52.7804","article-title":"Shifting patterns in the interpretation of phase III clinical trial outcomes in advanced non-small-cell lung cancer: the bar is dropping","volume":"32","author":"Sacher","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"10.1016\/j.mayocp.2016.02.012_bib63","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1200\/JCO.2011.35.2393","article-title":"Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs","volume":"29","author":"Amir","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2016.02.012_bib64","doi-asserted-by":"crossref","first-page":"266","DOI":"10.7326\/0003-4819-108-2-266","article-title":"Guidelines for statistical reporting in articles for medical journals: amplifications and explanations","volume":"108","author":"Bailar","year":"1988","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.mayocp.2016.02.012_bib65","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1200\/JCO.2011.38.7571","article-title":"Progression-free survival: meaningful or simply measurable?","volume":"30","author":"Booth","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.mayocp.2016.02.012_bib66","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju331","article-title":"Use and misuse of waterfall plots","volume":"106","author":"Shao","year":"2014","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.mayocp.2016.02.012_bib67","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/nrclinonc.2011.21","article-title":"Antiangiogenic therapy: impact on invasion, disease progression, and metastasis","volume":"8","author":"Ebos","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"issue":"15","key":"10.1016\/j.mayocp.2016.02.012_bib68","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1212\/WNL.0b013e3181bc0184","article-title":"Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma","volume":"73","author":"Iwamoto","year":"2009","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.mayocp.2016.02.012_bib69","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1200\/JCO.2010.30.2794","article-title":"Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials","volume":"29","author":"Miles","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.mayocp.2016.02.012_bib70","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1001\/jama.2012.9658","article-title":"The safety risks of innovation: the FDA's Expedited Drug Development Pathway","volume":"308","author":"Moore","year":"2012","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.mayocp.2016.02.012_bib71","doi-asserted-by":"crossref","first-page":"625","DOI":"10.6004\/jnccn.2013.0077","article-title":"Double-crossed: why crossover in clinical trials may be distorting medical science","volume":"11","author":"Prasad","year":"2013","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.mayocp.2016.02.012_bib72","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cct.2013.12.003","article-title":"The misguided ethics of crossover trials","volume":"37","author":"Prasad","year":"2014","journal-title":"Contemp Clin Trials"},{"issue":"5","key":"10.1016\/j.mayocp.2016.02.012_bib73","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.mayocp.2016.02.012_bib74","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.mayocp.2015.08.017","article-title":"Characteristics of exceptional or super responders to cancer drugs","volume":"90","author":"Prasad","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.mayocp.2016.02.012_bib75","unstructured":"US Government Accountability Office. New drug apporval: FDA needs to enhance its oversight of drugs approved on the basis of surrogate endpoints. http:\/\/www.gao.gov\/new.items\/d09866.pdf. Published September 2009. Accessed July 25,\u00a02015."}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619616001257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619616001257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T14:28:02Z","timestamp":1536676082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619616001257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":75,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0025619616001257"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2016.02.012","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2016.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}